Invivyd, Inc. Common Stock

IVVDNASDAQ • USD
0.81 USD
↘ 0.03 (3.91%)AT CLOSE (03:59 PM EDT)
0.82
↗ 0.01 (1.44%)
POST MARKET (AS OF 04:27 PM EDT)
Post Market
AS OF 04:27 PM EDT
0.82
↗ 0.01 (1.44%)
🟢Market: OPEN

IVVD is currently priced at $0.82. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest IVVD is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 5, 2026.

Open?$0.85
High?$0.85
Low?$0.80
Prev. Close?$0.84
Volume?4.2M
Avg. Volume?6.1M
VWAP?$0.82
Rel. Volume?0.69x
Bid / Ask
Bid?$0.70 × 100
Ask?$0.96 × 100
Spread?$0.26
Midpoint?$0.83
Valuation & Ratios
Market Cap?247.6M
Shares Out?294.8M
Float?229.7M
Float %?78.0%
P/E Ratio?N/A
P/B Ratio?1.37
EPS?-$0.36
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Employees
122
Market Cap
247.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-08-06
Address
209 CHURCH STREET
NEW HAVEN, CT 06510
Phone: (781) 819-0080
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
48
Short Sent.?
34
Piotroski F-Score?2/9Weak
Altman Z-Score?-3.33Distress
Confidence?59%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?13.30%High
Short Interest?30.6M
Days to Cover?7.7
Free Float229.7M
Avg Daily Volume4.0M
Settlement Date2026-09-15
Financial Health
Current Ratio?5.87Strong
Quick Ratio?5.87Strong
Cash Ratio?5.16Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
Peers
100
S&P
90
1.37CHEAP▾
P/S?
Peers
100
S&P
36
4.24FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.8CHEAP▾
EV/Sales?
Peers
100
S&P
84
1.50CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-59.3%WEAK▾
ROA?
S&P
3
-49.0%WEAK▾
Cash Flow & Enterprise
FCF?$-109658000
Enterprise Value?$87.5M
Fundamentals ratios updated end of day